Inhibition of protein kinase C activator-mediated induction of p21(CIP1) and p27(KIP1) by deoxycytidine analogs in human leukemia cells: Relationship to apoptosis and differentiation

Biochemical Pharmacology

Volumn 58, Issue 1, 1999, Pages 121-131

  Vrana, Julie A ^a   Kramer, Lora B ^a   Saunders, Aida M ^a   Zhang, Xiao Fan ^a   Dent, Paul ^a   Povirk, Lawrence F ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; ara C; Bryostatin; Differentiation; Gemcitabine; p21(CIP1); p27(KIP1); PMA; U937 cells

Indexed keywords

APHIDICOLIN; BRYOSTATIN 1; CYCLIN DEPENDENT KINASE; CYCLINE; CYTARABINE; ETOPOSIDE; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEOSIDE ANALOG; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; PROTEIN P21; PROTEIN P27;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; CYTARABINE; DEOXYCYTIDINE; DRUG INTERACTIONS; ENZYME ACTIVATION; HUMANS; LACTONES; LEUKEMIA; MACROLIDES; MICROTUBULE-ASSOCIATED PROTEINS; MITOGENS; PROTEIN KINASE C; TETRADECANOYLPHORBOL ACETATE; TUMOR SUPPRESSOR PROTEINS; U937 CELLS;

EID: 0033168213     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00077-5     Document Type: Article

References (65)

1. Martin S.J., Bradley J.G., Cotter T.G. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol. 79:1990;448-453.
2. Solary E., Bertrand R., Pommier Y. Apoptosis of human leukemic HL-60 cells induced to differentiate by phorbol ester treatment. Leukemia. 8:1994;792-797.
3. Selvakumaran M., Reed J.C., Liebermann D., Hoffman B. Progression of the myeloid differentiation program is dominant to transforming growth factor-β-1-induced apoptosis in M1 myeloid leukemic cells. Blood. 84:1994;1036-1042.
4. Lopes U.G., Erhardt P., Yao R., Cooper G.M. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 272:1997;12893-12896.
5. Solary E., Bertrand R., Kohn K.W., Pommier Y. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood. 81:1993;1359-1368.
6. de Vente J., Kiley S., Garris T., Bryant W., Hooker J., Posekany K., Parker P., Cook P., Fletcher D., Ways D.K. Phorbol ester treatment of U937 cells with altered protein kinase C content and distribution induces cell death rather than differentiation. Cell Growth Differ. 6:1995;371-382.
7. Hoffman B., Liebermann D.A. Molecular controls of apoptosis Differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive and negative modulators . Oncogene. 9:1994;1807-1812.
8. 3 correlates with reduced rate of maturation of DNA replication intermediates. Cancer Res. 51:1991;3451-3455.
9. Yang G.S., Minden M.D., McCulloch E.A. Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. Leukemia. 7:1993;1012-1019.
10. Waxman S., Huang Y., Scher B.M., Scher M. Enhancement of differentiation and cytotoxicity of leukemia cells by combinations of fluorinated pyrimidines and differentiation inducers Development of DNA double-strand breaks . Biomed Pharmacother. 46:1992;183-192.
11. Bhatia U., Traganos F., Darzynkiewicz Z. Induction of cell differentiation potentiates apoptosis triggered by prior exposure to DNA-damaging drugs. Cell Growth Differ. 6:1995;937-944.
12. Sun Y., Pommier Y., Colburn N.H. Acquisition of a growth-inhibitory response to phorbol ester involves DNA damage. Cancer Res. 52:1992;1907-1915.
13. Kraft A.S., William F., Pettit G.R., Lilly M.B. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res. 49:1989;1287-1293.
14. Dale I.L., Bradshaw T.D., Gescher A., Pettit G.R. Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A5449 human lung carcinoma cells. Cancer Res. 49:1989;3242-3245.
15. Christian M.C., Pluda J.M., Ho P.T., Arbuck S.G., Murgo A.J., Sausville E.A. Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute. Semin Oncol. 24:1997;219-240.
16. Asiedu C., Biggs J., Lilly M., Kraft A.S. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res. 55:1995;3716-3720.
17. Ng S.B., Guy G.R. Two protein kinase C activators, bryostatin-1 and phorbol-12-myristate-13-acetate, have different effects on hemopoietic cell proliferation and differentiation. Cell Signal. 4:1992;405-416.
18. Carey J.O., Posekany K.J., deVente J.E., Pettit G.R., Ways D.K. Phorbol-ester-stimulated phosphorylation of PU.1 Association with leukemic cell growth inhibition . Blood. 87:1996;4316-4324.
19. Grant S., Turner A.J., Freemerman A.J., Wang Z., Kramer L., Jarvis W.D. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1 Relationship to differentiation and ara-C-induced apoptosis . Exp Cell Res. 228:1996;65-75.
20. Vrana J.A., Saunders A.M., Chellappan S.P., Grant S. Divergent effects of bryostatin 1 and PMA on cell cycle arrest and maturation in human myeloid leukemia cells (U937). Differentiation. 63:1998;33-42.
21. Jarvis W.D., Povirk L.F., Turner A.J., Traylor R.S., Gewirtz D.A., Pettit G.R., Grant S. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol. 47:1994;839-852.
22. Han Z.T., Zhu X.X., Yang R.Y., Sun J.Z., Tian G.F., Liu X.J., Cao G.S., Newmark H.L., Conney A.H., Chang R.L. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia Preliminary studies on therapeutic efficacy and toxicity . Proc Natl Acad Sci USA. 95:1998;5357-5361.
23. Sundstrom C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U937). Int J Cancer. 17:1976;565-577.
24. Freemerman A.J., Vrana J.A., Tombes R.M., Jiang H., Chellappan S.P., Fisher P.B., Grant S. Effects of antisense p21 (Waf1/Cip1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60). Leukemia. 11:1997;504-513.
25. Escher D., Schaffner W. Improved "activator trap" method for the isolation of transcriptional activation domains from random DNA fragments. Biotechniques. 21:1996;848-854.
26. Mueller P.R., Wold B. In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science. 246:1989;780-786.
27. Kariya Y., Kato K., Hayashizaki Y., Himeno S., Tarui S., Matsubara K. Revision of consensus sequence of human Alu repeats - a review. Gene. 53:1987;1-10.
28. Hornstra I.K., Yang T.P. In vivo footprinting and genomic sequencing by ligation-mediated PCR. Anal Biochem. 213:1993;179-193.
29. Khym J.X. An analytical system for rapid separation of tissue nucleotides at low pressures on conventional anion exchangers. Clin Chem. 21:1975;1245-1252.
30. Plunkett W., Hug V., Keating M.J., Chubb S. Quantitation of 1-[β-D-arabinofuranosyl]cytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-[β-D-arabinofuranosyl]cytosine therapy. Cancer Res. 40:1980;588-591.
31. Bunch R.T., Eastman A. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ. 8:1997;779-788.
32. Grant S., Jarvis W.D., Swerdlow P.S., Turner A.J., Traylor R.S., Wallace H.J., Lin P.-S., Pettit G.R., Gewirtz D.A. Potentiation of the activity of 1-[β-D-arabinofuranosyl]cytosine by the macrocyclic lactone PKC activator bryostatin 1 in HL-60 cells Association with enhanced fragmentation of mature DNA . Cancer Res. 52:1992;6270-6278.
33. Jarvis W.D., Fornari F.A., Auer K.L., Freemerman A.J., Szabo E., Birrer M.J., Johnson C.R., Barbour S.E., Dent P., Grant S. Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Mol Pharmacol. 52:1997;935-947.
34. Drew H.R., Travers A.A. DNA structural variations in the E. coli tyrT promoter. Cell. 37:1984;491-502.
35. Strätling W.H., Grade C., Hörz W. Ca/Mg-dependent endonuclease from porcine liver. Purification, properties, and sequence specificity. J Biol Chem. 259:1984;5893-5898.
36. Yin D.X., Schimke R.T. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res. 55:1995;4922-4928.
37. Brunet C.L., Gunby R.H., Benson R.S.P., Hickman J.A., Watson A.J.M., Brady G. Commitment to cell death measured by loss of clonogenicity is separable from the appearance of apoptotic markers. Cell Death Differ. 5:1998;107-115.
38. Jiang H., Lin J., Su Z.Z., Collart F.R., Huberman E., Fisher P.B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene. 9:1994;3397-3406.
39. KIP1 and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells. J Biol Chem. 272:1997;9424-9435.
40. KIP1 on resistance of tumor cells to anticancer agents. Nat Med. 2:1996;1204-1209.
41. Waldman T., Lengauer C., Kinzler K.W., Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381:1996;713-716.
42. Ruan S., Okcu M.F., Ren J.P., Chiao P., Andreeff M., Levin V., Zhang W. Overexpressed WAF1/CIP1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res. 58:1998;1538-1543.
43. Steinman R.A., Hoffman B., Iro A., Guillouf C., Liebermann D.A., el-Houseini M.E. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene. 9:1994;3389-3396.
44. Griffin J., Munroe D., Major P., Kufe D. Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis. Exp Hematol. 10:1982;774-781.
45. Waga S., Hannon G.J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:1994;574-578.
46. Li R., Hannon G.J., Beach D., Stillman B. Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr Biol. 6:1996;189-199.
47. Loor G., Zhang S.J., Zhang P., Toomey N.L., Lee M.Y. Identification of DNA replication and cell cycle proteins that interact with PCNA. Nucleic Acids Res. 25:1997;5041-5046.
48. Elledge S.J. Cell cycle checkpoints Preventing an identity crisis . Science. 274:1996;1664-1672.
49. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
50. Bravo R., Macdonald-Bravo H. Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle Association with DNA replication sites . J Cell Biol. 105:1987;1549-1554.
51. Ikegami S., Taguchi T., Ohashi M., Oguro M., Nagano H., Mano Y. Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-α Nature. 275:1978;458-460.
52. WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res. 56:1996;31-35.
53. Ravi R.K., Weber E., McMahon M., Williams J.R., Baylin S., Mal A., Harter M.L., Dillehay L.E., Claudio P.P., Giordano A., Nelkin B.D., Mabry M. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest. 101:1998;153-159.
54. 2+-dependent endonuclease activity during the early stages of murine erythroleukemic cell differentiation. Proc Natl Acad Sci USA. 81:1984;7461-7465.
55. Chiba P., Tihan T., Eher R., Koller U., Wallner C., Gobl R., Linkesch W. Effect of cell growth and cell differentiation on 1-[β-D-arabinofuranosyl]cytosine metabolism in myeloid cells. Br J Haematol. 71:1989;451-455.
56. Kasten M.M., Giordano A. pRb and the Cdks in apoptosis and the cell cycle. Cell Death Differ. 5:1998;132-140.
57. 1. Mol Cell Biol. 8:1988;1614-1624.
58. Wang Z., Su Z.-Z., Fisher P.B., Wang S., VanTuyle G., Grant S. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 in the reciprocal regulation of PKC activator-induced apoptosis and differentiation in human myelomonocytic leukemia cells. Exp Cell Res. 244:1998;105-116.
59. Wang J., Walsh K. Resistance to apoptosis is conferred by CDK inhibitors during myocyte differentiation. Science. 273:1996;359-361.
60. Furth J.J., Cohen S.S. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-[β-D-arabinofuranosyl]cytosine and the 5′-triphosphate of 9-[β-D-arabinofuranosyl]adenine. Cancer Res. 28:1968;2061-2067.
61. Kaufmann S.H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs A cautionary note . Cancer Res. 49:1989;5870-5878.
62. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK p38 MAP kinases on apoptosis. Science. 270:1995;1326-1331.
63. Kharbanda S., Emoto Y., Kisaki H., Saleem A., Kufe D. 1-β-D-Arabinofuranosylcytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol ester-resistant myeloid leukemia cells. Mol Pharmacol. 46:1994;67-72.
64. Grant S., Roberts J., Poplin E., Tombes M.B., Kyle B., Welch D., Carr M., Bear H.D. Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin Cancer Res. 4:1998;611-618.
65. Han Z.T., Tong Y.K., He L.M., Zhang Y., Sun J.Z., Wang T.Y., Zhang H., Cui Y.L., Newmark H.L., Conney A.H., Chang R.L. 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs. Proc Natl Acad Sci USA. 95:1998;5362-5365.